Effects of Liraglutide on Heart Rate and Heart Rate Variability: A Randomized, Double-Blind, Placebo-Controlled Crossover Study
Research output: Contribution to journal › Journal article › Research › peer-review
Standard
Effects of Liraglutide on Heart Rate and Heart Rate Variability : A Randomized, Double-Blind, Placebo-Controlled Crossover Study. / Kumarathurai, Preman; Anholm, Christian; Larsen, Bjørn Strøier; Olsen, Rasmus Huan; Madsbad, Sten; Kristiansen, Ole; Nielsen, Olav W; Haugaard, Steen B; Sajadieh, Ahmad.
In: Diabetes Care, Vol. 40, No. 1, 01.2017, p. 117-124.Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Effects of Liraglutide on Heart Rate and Heart Rate Variability
T2 - A Randomized, Double-Blind, Placebo-Controlled Crossover Study
AU - Kumarathurai, Preman
AU - Anholm, Christian
AU - Larsen, Bjørn Strøier
AU - Olsen, Rasmus Huan
AU - Madsbad, Sten
AU - Kristiansen, Ole
AU - Nielsen, Olav W
AU - Haugaard, Steen B
AU - Sajadieh, Ahmad
N1 - © 2017 by the American Diabetes Association.
PY - 2017/1
Y1 - 2017/1
N2 - OBJECTIVE: Reduced heart rate variability (HRV) and increased heart rate (HR) have been associated with cardiovascular mortality. Glucagon-like peptide 1 receptor agonists (GLP-1 RAs) increase HR, and studies have suggested that they may reduce HRV. We examined the effect of the GLP-1 RA liraglutide on HRV and diurnal variation of HR in overweight patients with newly diagnosed type 2 diabetes (T2D) and stable coronary artery disease (CAD).RESEARCH DESIGN AND METHODS: Liraglutide or placebo was administrated to a backbone therapy of metformin in this double-blind, placebo-controlled 12 + 12-week crossover study. SD of beat-to-beat (NN) intervals (SDNN) was assessed by 24-h Holter monitoring as a measure of HRV. Diurnal HR variation and sympathovagal balance analyzed by root mean square of successive differences (RMSSD) in NN intervals and high-frequency (HF) and low-frequency (LF) power were assessed.RESULTS: Compared with placebo, liraglutide decreased SDNN in 27 subjects (-33.9 ms; P < 0.001, paired analysis); decreased RMSSD (-0.3 log-ms; P = 0.025); and increased the mean HR (8.1 beats/min; P = 0.003), daytime HR (5.7; P = 0.083), and nighttime HR (6.3; P = 0.026). In a multivariable regression analysis, the decrease in SDNN remained significant after adjustment for metabolic and HR changes. Liraglutide reduced HF power (-0.7 log-ms(2); P = 0.026) without any change in LF/HF ratio.CONCLUSIONS: In overweight patients with CAD and newly diagnosed T2D, liraglutide increased HR and reduced HRV despite significant weight loss and improvement in metabolic parameters. The increase in nightly HR in conjunction with a decrease in parameters of parasympathetic activity suggests that liraglutide may affect sympathovagal balance.
AB - OBJECTIVE: Reduced heart rate variability (HRV) and increased heart rate (HR) have been associated with cardiovascular mortality. Glucagon-like peptide 1 receptor agonists (GLP-1 RAs) increase HR, and studies have suggested that they may reduce HRV. We examined the effect of the GLP-1 RA liraglutide on HRV and diurnal variation of HR in overweight patients with newly diagnosed type 2 diabetes (T2D) and stable coronary artery disease (CAD).RESEARCH DESIGN AND METHODS: Liraglutide or placebo was administrated to a backbone therapy of metformin in this double-blind, placebo-controlled 12 + 12-week crossover study. SD of beat-to-beat (NN) intervals (SDNN) was assessed by 24-h Holter monitoring as a measure of HRV. Diurnal HR variation and sympathovagal balance analyzed by root mean square of successive differences (RMSSD) in NN intervals and high-frequency (HF) and low-frequency (LF) power were assessed.RESULTS: Compared with placebo, liraglutide decreased SDNN in 27 subjects (-33.9 ms; P < 0.001, paired analysis); decreased RMSSD (-0.3 log-ms; P = 0.025); and increased the mean HR (8.1 beats/min; P = 0.003), daytime HR (5.7; P = 0.083), and nighttime HR (6.3; P = 0.026). In a multivariable regression analysis, the decrease in SDNN remained significant after adjustment for metabolic and HR changes. Liraglutide reduced HF power (-0.7 log-ms(2); P = 0.026) without any change in LF/HF ratio.CONCLUSIONS: In overweight patients with CAD and newly diagnosed T2D, liraglutide increased HR and reduced HRV despite significant weight loss and improvement in metabolic parameters. The increase in nightly HR in conjunction with a decrease in parameters of parasympathetic activity suggests that liraglutide may affect sympathovagal balance.
KW - Journal Article
U2 - 10.2337/dc16-1580
DO - 10.2337/dc16-1580
M3 - Journal article
C2 - 27797930
VL - 40
SP - 117
EP - 124
JO - Diabetes Care
JF - Diabetes Care
SN - 0149-5992
IS - 1
ER -
ID: 176438341